Kouichi Tamura

Summary

Affiliation: Yokohama City University
Country: Japan

Publications

  1. Azushima K, Ohki K, Wakui H, Uneda K, Haku S, Kobayashi R, et al. Adipocyte-Specific Enhancement of Angiotensin II Type 1 Receptor-Associated Protein Ameliorates Diet-Induced Visceral Obesity and Insulin Resistance. J Am Heart Assoc. 2017;6: pubmed publisher
    ..Consequently, adipose tissue ATRAP is suggested to be an effective therapeutic target for the treatment of visceral obesity. ..
  2. Tamura K, Tsurumi Ikeya Y, Wakui H, Maeda A, Ohsawa M, Azushima K, et al. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. Ther Apher Dial. 2013;17:185-92 pubmed publisher
  3. request reprint
    Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, et al. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 2013;19:3043-8 pubmed
    ..These results suggest the clinical potential benefit of an ATRAP activation strategy in the treatment of hypertension and related organ injury. ..
  4. Tamura K, Yamauchi J, Tsurumi Ikeya Y, Sakai M, Ozawa M, Shigenaga A, et al. Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomerulopathy. Clin Exp Hypertens. 2008;30:33-43 pubmed publisher
  5. Azushima K, Tamura K, Haku S, Wakui H, Kanaoka T, Ohsawa M, et al. Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: a multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2). Atherosclerosis. 2015;240:297-304 pubmed publisher
    ..This is the first report suggesting that an integrative medicine approach may exert favorable effects on obesity-related hypertension compared with conventional pharmaceutical treatment. UMIN000003878. ..
  6. request reprint
    Tamura K, Wakui H, Azushima K, Uneda K, Haku S, Kobayashi R, et al. Angiotensin II Type 1 Receptor Binding Molecule ATRAP as a Possible Modulator of Renal Sodium Handling and Blood Pressure in Pathophysiology. Curr Med Chem. 2015;22:3210-6 pubmed
  7. Ohsawa M, Tamura K, Wakui H, Kanaoka T, Azushima K, Uneda K, et al. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia. Lipids Health Dis. 2015;14:161 pubmed publisher
  8. Haruhara K, Wakui H, Azushima K, Kurotaki D, Kawase W, Uneda K, et al. Angiotensin receptor-binding molecule in leukocytes in association with the systemic and leukocyte inflammatory profile. Atherosclerosis. 2018;269:236-244 pubmed publisher
    ..These results suggest that leukocyte ATRAP is an emerging marker capable of reflecting the systemic and leukocyte inflammatory profile, and plays a role as an anti-inflammatory factor in the pathophysiology of NCDs. ..
  9. Ohki K, Wakui H, Kishio N, Azushima K, Uneda K, Haku S, et al. Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. Sci Rep. 2018;8:2846 pubmed publisher
    ..Hyperactivity of AT1 receptor could be related to formation of insulin resistance related to metabolic syndrome. ..

More Information

Publications13

  1. request reprint
    Tamura K, Chen Y, Tanaka Y, Sakai M, Tsurumi Y, Koide Y, et al. Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. Mol Cell Endocrinol. 2004;224:11-20 pubmed
    ..These results suggest that LXRalpha plays an important role in the cAMP-mediated regulation of human renin gene transcription by binding to CNRE. ..
  2. Kobayashi R, Wakui H, Azushima K, Uneda K, Haku S, Ohki K, et al. An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model. Kidney Int. 2017;91:1115-1125 pubmed publisher
    ..Thus, renal ATRAP downregulation is involved in the onset and progression of blood pressure elevation caused by renal mass reduction, and implicates ATRAP as a therapeutic target for hypertension in chronic kidney disease. ..
  3. Ohki K, Wakui H, Azushima K, Uneda K, Haku S, Kobayashi R, et al. ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice. Int J Mol Sci. 2017;18: pubmed publisher
    ..Future studies that modulate ATRAP in WAT are necessary to assess its in vivo functions in the development of obesity-related metabolic disorders. ..
  4. Ishii T, Taguri M, Tamura K, Oyama K. Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model. Sci Rep. 2017;7:14004 pubmed publisher
    ..24 (95% confidence interval: 0.15-0.38) in all cohorts. These results suggest that XORi improved all-cause mortality in end-stage renal disease, irrespective of the serum UA level. ..